McKesson Corporation (MCK) Hit a 52 Week High, Can the Run Continue?

McKesson shares rose 15.2% over the past month and reached a 52-week high of $1,121.50; the stock is up 30.7% year to date, outperforming its sector and industry. In its November 4, 2026 report, EPS was $11.68 versus the $10.69 consensus, and estimates point to EPS growth of 15.72% this fiscal year and 12.29% next year. Zacks rates the shares #2 (Buy), though valuation is above peers, including 23.7x current-year EPS estimates versus 18x for the industry.

Analysis

The key underwriting question is whether expected per-share growth comes from durable operating improvement or from factors such as mix, cost control, and share-count reduction. With revenue growth forecast below EPS growth, verify segment operating margins, diluted share count, and free-cash-flow conversion before treating estimate momentum as evidence of a structurally higher growth rate. In pharmaceutical distribution, throughput can be large while economics remain sensitive to contract terms, customer mix, and working-capital swings; earnings beats alone do not establish that those risks have improved.

The premium valuation leaves less room for execution slippage than for a lower-multiple distributor. A near-term pause after the sharp run is plausible, particularly if estimate revisions stop rising; a new high by itself is not a catalyst. Over 1–3 months, the next earnings update and revisions to margin and cash-flow assumptions matter more than the headline EPS beat. Over 6–18 months, specialty-drug mix and contract economics could support the premium, but should be demonstrated in reported results. Compare McKesson with Cardinal Health and Cencora on normalized earnings growth, cash conversion, and business mix before expressing a relative-value view. The thesis weakens if guidance or consensus revisions turn down, margins contract, or cash conversion deteriorates; it strengthens if earnings growth is accompanied by sustained margin and cash-flow improvement.

Key Decisions for Investors

• Do not chase strength solely on estimate-beat history. For existing longs, consider taking partial profits or using a defined-risk collar if the position has become oversized; the principal risk is multiple compression if growth expectations falter.
• Keep MCK on a pullback watchlist rather than setting a price target. Reassess after the next earnings release using operating-margin trends, diluted share count, and free-cash-flow conversion; renewed estimate increases supported by those metrics would improve the entry case.
• Treat a relative-value short against Cardinal Health or Cencora as conditional, not an immediate trade: first compare current valuation, growth, mix, and cash conversion on consistent periods. Avoid the pair if MCK's reported operating performance is demonstrably stronger.
• Falsification alert: reduce the bullish thesis if management guidance or consensus estimates are cut, or if margin and cash-flow metrics fail to support per-share growth; sustained operational improvement alongside rising estimates would argue against fading the rally.